Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.27.4 (
ribonuclease
)
6,621
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The distribution of the mRNA of the specific thyrotropin-releasing-hormone (TRH)-degrading enzyme
pyroglutamyl peptidase II
(
EC 3.4.19.6
) in rat tissues and brain regions and its regulation in rat tissues and in GH3 cells was studied by a reliable and quantitative solution hybridization
ribonuclease
protection assay. The distribution of
pyroglutamyl peptidase II
mRNA levels was uneven with the highest level of mRNA found in brain. Within brain the distribution of
pyroglutamyl peptidase II
mRNA was heterogeneous. A single dose of T3 markedly increased the level of
pyroglutamyl peptidase II
mRNA in the pituitary (p < 0.01) and in the liver (p < 0.05). In GH3 cells, exposure to T3 at concentrations from 10(-10) to 10(-6) M for time periods of 2-24 h, did not change
pyroglutamyl peptidase II
mRNA levels. Acute administration of TRH to rats had no effect on
pyroglutamyl peptidase II
mRNA levels. By contrast, TRH down-regulated
pyroglutamyl peptidase II
mRNA in GH3 cells. A similar effect was produced in GH3 cells by activators of protein kinase C. These studies reveal fundamental differences in the mechanism of regulation of
pyroglutamyl peptidase II
mRNA in pituitary and in GH3 cells. Elevation of
pyroglutamyl peptidase II
mRNA in liver by T3 suggests that this organ is the source of the enzyme in serum.
...
PMID:Quantitation and regulation of pyroglutamyl peptidase II messenger RNA levels in rat tissues and GH3 cells. 963 Apr 37